What changed in the XENE analyst rating on March 9, 2026?

Three firms maintained **Buy** on Xenon on March 9, 2026. Guggenheim raised its price target to **$90**, BofA to **$77**, and Jefferies reiterated **Buy** with a potential **+50-75%** upside.

Do the maintained Buy ratings guarantee gains for XENE investors?

No. Maintained Buy ratings signal analyst confidence, but biotech outcomes depend on trial results and deals. Use risk limits and verify catalysts before investing.

How does Meyka incorporate the XENE analyst rating into its grade?

Meyka uses analyst consensus, sector performance, growth metrics, and S&P 500 comparisons to assign grades. Meyka AI rates **XENE with a grade of B**, reflecting balanced upside and risk.

Where can I read the analyst notes cited in this article?

See the analyst write-ups at StreetInsider for details on the price targets and rationale. For Guggenheim and BofA coverage, consult the linked notes in the article.

Analyst Ratings

Guggenheim Maintains Buy on Xenon Pharmaceuticals Inc. (XENE) March 2026

ByHuzaifa Zahoor March 10, 2026March 10, 2026

Three leading firms maintained Buy ratings on Xenon Pharmaceuticals Inc. (XENE) on March 9, 2026, a coordinated show of analyst support. The XENE analyst rating headlines include a $90 price target from Guggenheim and a $77 target from Bank of America Securities. Jefferies also reiterated Buy and flagged a potential +50-75% stock move. These actions give investors clearer near-term upside signals for XENE analyst rating and set expectations for upcoming catalysts.